Interpretation of the 2022 ETA/ATA consensus on the management of thyroid eye disease
10.3760/cma.j.cn311282-20230329-00140
- VernacularTitle:2022年ETA/ATA甲状腺眼病诊治共识解读
- Author:
Yaosheng LUO
1
;
Zhangfang LI
;
Jie SHEN
Author Information
1. 广州医科大学附属第二医院内分泌科 510260
- Keywords:
Thyroid eye disease;
Treatment consensus;
Biological agent
- From:
Chinese Journal of Endocrinology and Metabolism
2023;39(7):555-559
- CountryChina
- Language:Chinese
-
Abstract:
In December 2022, the European Thyroid Association(ETA) and American Thyroid Association(ATA) jointly released a consensus statement on the diagnosis and management of thyroid eye disease(TED). Taking into account the benefits and risks, the consensus provides specific recommendations for essential therapeutic agents. It also covers 34 key recommendations on the diagnosis and treatment decision-making, basic therapy and care, and risk factor control for TED.
